Healthscope Limited
(ASX:HSO) has tied up the sale of its Australian pathology operations to Crescent Capital Partners.
The private hospital operator announced the $105 million deal at the end of last month as part of its strategy to focus on its core hospitals business.
The operations include about 550 collection centres and 31 laboratories in Victoria, South Australia, New South Wales and the Northern Territory.
At the time of the sale Healthscope affirmed its commitment to the company’s International Pathology operations which it believes have consistently performed well over time.
Healthscope reported a net profit of $58.56 million in the first half of the 2015 financial year.
